Kura Oncology, Inc. (KURA)

The past six months have seen several significant events impacting Kura Oncology's stock price. The FDA approved KOMZIFTI, leading to investor enthusiasm and a stock increase. Kura Oncology launched KOMZIFTI and reported $2.1 million in net product revenue. The company received $195 million in milestone payments from Kyowa Kirin. Analysts issued positive ratings and raised price targets for KURA stock. KURA insiders have traded the stock 16 times, with 3 purchases and 13 sales. Kura Oncology reported financial results for Q3 2025, with the New Drug Application for ziftomenib remaining under FDA Priority Review, and missed GAAP revenue estimates in Q2 2025.

Demand for Kura Oncology's products is driven by the prevalence and incidence of specific cancer types and the efficacy of its treatments, rather than seasonal fluctuations. The FDA approval and commercial launch of KOMZIFTI indicate consistent demand based on patient need.

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines for cancer treatment. The company's pipeline includes small-molecule product candidates targeting cancer signaling pathways, such as KOMZIFTI™ (ziftomenib) for relapsed or refractory NPM1-mutated AML, Tipifarnib for HRAS-mutant head and neck squamous cell carcinoma, KO-539 for acute myeloid leukemia, KO-947 for mitogen-activated protein kinase pathway tumors, KO-2806 for solid tumors like renal cell carcinoma, and KO-7246 for diabetes and cardiometabolic diseases.

Kura Oncology, Inc. is headquartered in San Diego, California, and has an office in Boston, Massachusetts. The company plans to expand its presence in key markets worldwide through partnerships and collaborations.

Kura Oncology's brand reputation has been positively influenced by clinical program developments and regulatory approvals. The FDA approval of KOMZIFTI generated positive sentiment among investors. Consistent positive analyst coverage reflects confidence in the company's pipeline. The strategic collaboration with Kyowa Kirin has enhanced Kura's reputation through funding and global reach.

Kura Oncology, Inc. has a mixed ownership structure. Approximately 69.17% of the company's stock is owned by institutional investors, with Vanguard owning the most shares. Insiders own approximately 2.28% of the company's stock. Public companies and individual investors own approximately 28.56% of the company's stock.